Checkpoint Therapeutics, Inc. - CKPT STOCK NEWS

Checkpoint Therapeutics announced positive results from its pivotal trial of cosibelimab, an anti-PD-L1 antibody, for treating metastatic cutaneous squamous cell carcinoma (cSCC) at the 2022 ASCO Annual Meeting. The trial included 78 patients across 24 sites and showed a confirmed objective response rate of 48.7%. Notably, 76% of these responses were ongoing at the time of analysis. The safety profile was generally favorable, with the most common adverse events being fatigue and rash. A Biologics License Application is planned for submission in Q4 2022.

Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) announced that CEO James Oliviero will present a company overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 3:00 p.m. ET. The management team will also engage in one-on-one meetings. A live webcast of the presentation can be accessed on Checkpoint's website for about 30 days post-event. Checkpoint focuses on novel oncology treatments, including the evaluation of cosibelimab and olafertinib for solid tumor cancers.

Checkpoint Therapeutics announces it has received waivers for pediatric clinical studies from the EMA and MHRA for cosibelimab in cutaneous squamous cell carcinoma (cSCC). This decision allows Checkpoint to expedite marketing authorization applications without the need for costly pediatric trials in Europe. Positive topline data from a recent clinical trial supports their upcoming Biologics License Application (BLA) later this year. Cosibelimab is a promising anti-PD-L1 therapy aimed at enhancing immune response against cSCC.

Checkpoint Therapeutics (CKPT) reported positive topline results from its registration-enabling study of cosibelimab for metastatic cutaneous squamous cell carcinoma (cSCC), expecting to submit a Biologics License Application (BLA) in 2022. As of March 31, 2022, the company had $41.5 million in cash, down from $54.7 million. R&D expenses rose significantly to $14.7 million from $4.2 million year-over-year, while net loss increased to $16.8 million, or $0.20 per share. The company remains focused on advancing its oncology pipeline with a disruptive pricing strategy.

Checkpoint Therapeutics (CKPT) announced that the pivotal trial results of cosibelimab for metastatic cutaneous squamous cell carcinoma (cSCC) will be presented at the 2022 ASCO Annual Meeting, scheduled for June 3-7, 2022. Following positive topline data revealed in January 2022, a Biologics License Application (BLA) submission is planned for later this year. Cosibelimab is a fully-human monoclonal antibody designed to block PD-L1, aiming to restore anti-tumor T cell responses. cSCC represents a significant health concern, with an estimated 40,000 advanced cases annually in the U.S.

Checkpoint Therapeutics (NASDAQ: CKPT) announced participation in the Fortress Biotech Virtual R&D Summit on April 5-6, 2022. Management will present a corporate overview and join a panel discussion on April 6 at 2:15 p.m. ET. The Summit highlights Fortress' diverse pipeline. Checkpoint's lead product, cosibelimab, is in a Phase 1 trial for recurrent or metastatic cancers, with plans to submit a Biologics License Application for cutaneous squamous cell carcinoma later this year. The webcast will be available on their Investor Relations page for 30 days post-event.

Checkpoint Therapeutics (CKPT) reported its financial results for the year ended December 31, 2021, highlighting a net loss of $56.7 million ($0.75 per share), up from $23.1 million ($0.41 per share) in 2020. The company increased its cash position to $54.7 million from $40.8 million a year prior. Significant developments include positive results for its anti-PD-L1 therapy, cosibelimab, in treating metastatic cutaneous squamous cell carcinoma, with a promising 47.4% objective response rate. The company plans to submit a Biologics License Application later in 2022.

Checkpoint Therapeutics (NASDAQ: CKPT), a clinical-stage immunotherapy and oncology company, announced participation by CEO James Oliviero in a fireside chat at B. Riley Securities’ Virtual Oncology Conference on January 27, 2022, at 11:00 a.m. EST. Management will also engage in one-on-one meetings during the event. A live webcast will be available for 30 days on Checkpoint's Investor Relations website. The company is focused on the development of innovative treatments for solid tumor cancers, including its lead product candidate, cosibelimab, which is undergoing clinical trials.

Checkpoint Therapeutics (NASDAQ: CKPT) announced promising outcomes from its clinical trial of cosibelimab for metastatic cutaneous squamous cell carcinoma (cSCC). The study achieved a primary endpoint with a 47.4% objective response rate. Safety results remain consistent with prior data, indicating manageable adverse events. A Biologics License Application (BLA) submission to the FDA is planned for later this year. The company aims to offer cosibelimab at a lower price compared to existing PD-(L)1 therapies, which may enhance market share. The ongoing study suggests significant potential for future market growth.